AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 SEP 19 - (NewsRx.com & NewsRx.net) --
by Michael Greer, senior medical writer - The HIV reverse transcriptase inhibitor tenofovir (or PMPA) can protect newborn primates from the simian form of HIV and may be able to perform the same function in human infants, researchers in California report.
"Simple affordable interventions are needed to reduce vertical human immunodeficiency virus (HIV) transmission in developing countries," according to Koen K. A. Van Rompay and colleagues at the California Regional Primate Research Center and Gilead Sciences Pharmaceuticals, which manufactures tenofovir.
Van Rompay and team showed that low doses of the drug were able to prevent infection in neonatal macaques, marking it as a candidate for such interventions.
The researchers compared the efficacy of tenofovir prophylaxis at several dose levels and administration points. Eight newborn macaques were given two 4-mg/kg doses of the reverse transcriptase inhibitor before and after challenge with the virulent SIV[mac251] strain, they said, while one neonate received a 30-mg/kg dose one hour after challenge.
Although Van Rompay and coworkers saw acute signs of infection, most of the macaques studied were seronegative at the ages of 19 to 23 months. This included three of four newborns given two low doses four hours ...
Source: HighBeam Research, Tenofovir Can Protect Macaque Infants.(from simian form of HIV)